ArticleAsian journal of neurosurgery2025
Clinico-Histomorphological and Mib-1 Analysis of Recurrent Meningiomas: A Retrospective Study.
Article in Asian journal of neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Meningiomas are the most common primary brain tumors in adults, comprising 37.6% of central nervous system neoplasms. Though gross total resection is the treatment of choice, meningiomas recur even after complete resection. Additionally, meningiomas with a high Ki67/MIB-1 labeling index (LI) have a higher recurrence rate. Aims: This article analyzes the clinico-histomorphological features of recurrent meningiomas and compares the expression of MIB-1 LI of primary and recurrent tumors. Materials and Methods: This was a retrospective observational study of 50 recurrent meningiomas diagnosed between 2019 and 2023. Tumors were analyzed for site, radiological/histopathological features, and expression of MIB-1 LI in both primary and recurrent tumors. Results: Thirty-four percent of the recurrent cases were between 41 and 50 years of age, 58% of the recurrent cases were males. Recurrence was most commonly seen in the frontal region (26%; Conclusion: Although MIB-1 LI is not an independent criterion for tumor grading, it can be used as an additional tool to identify at-risk patients and recommend close follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.